Nika Pharmaceuticals, Inc (NIKA): Total Liabilities
$318.6K
As of 2025-12-31
$349.0K
As of 2026-09-30
+159.8%
3-year compound annual growth
+97.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $318.6K | +33.2% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $239.2K | +135.1% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $101.7K | +459.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $18.2K | -24.3% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $24.0K | +128.4% | 2023-04-10, Balance as of period end |
| 2020-12-31 | $10.5K | n/a | 2022-03-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Nika Pharmaceuticals, Inc (NIKA) | 2025-12-31 | $318.6K | +33.2% |
| Skinvisible, Inc. (SKVI) | 2025-12-31 | $10.39M | +10.8% |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $2.36M | +36.5% |
| Regen BioPharma Inc (RGBP) | 2025-09-30 | $6.56M | +21.9% |
| Cell Source, Inc. (CLCS) | 2024-12-31 | $18.82M | +19.1% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $1.61M | +19.2% |
| Bio Essence Corp (BIOE) | 2025-12-31 | $2.50M | -23.2% |
| Trafalgar International, Inc. (TRFA) | 2025-12-31 | $742.5K | -17.3% |
| Bioxytran, Inc (BIXT) | 2025-12-31 | $3.25M | +68.3% |
Compare NIKA, SKVI, BDPT, RGBP side by side · Screen every company in Pharmaceutical Preparations ↗